Moreover, given the association of PRAME expression with favorable outcomes in hematological diseases, directly targeting PRAME by small molecule inhibitors or gene silencing might not be as beneficial as compared with cytotoxic targeting of the tumor cells expressing PRAME. This evidence concerns the gene PRAME and hematologic disorder.